Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation

Patent Trial and Appeal Board upheld validity of four Acorda patents; district court judge to issue decision on five patents. Victory would block generic competition until 2025.

chess

Acorda Therapeutics Inc. won a second victory against hedge fund manager Kyle Bass but it is waiting for a district court ruling on the validity of five patents covering its multiple sclerosis drug Ampyra (dalfampridine). The outcome will determine if it will be free from generic competition until 2025.

In a March 9 final written decision, the US Patent and Trademark Office's Patent Trial and Appeal Board...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet